Recurrent ascites in a patient with low-grade astrocytoma and ventriculo-peritoneal shunt treated with the multikinase inhibitor sorafenib

J Pediatr Hematol Oncol. 2014 Nov;36(8):e533-5. doi: 10.1097/MPH.0000000000000094.

Abstract

This report describes a 6-year-old boy with disseminated low-grade astrocytoma and ventriculo-peritoneal shunt, who developed recurrent ascites while receiving sorafenib on a clinical trial. Laboratory analysis of the peritoneal fluid showed no elevation of protein content and no evidence of underlying infection or tumor dissemination. This report highlights ascites as a previously unrecognized adverse reaction to sorafenib in a patient with a ventriculo-peritoneal shunt. We conclude that such patients should be closely monitored for this complication when treated with sorafenib.

Trial registration: ClinicalTrials.gov NCT01338857.

Publication types

  • Case Reports
  • Clinical Trial, Phase II
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Ascites / chemically induced*
  • Ascites / pathology
  • Astrocytoma / drug therapy*
  • Brain Neoplasms / drug therapy*
  • Child
  • Humans
  • Magnetic Resonance Imaging
  • Male
  • Niacinamide / adverse effects
  • Niacinamide / analogs & derivatives*
  • Phenylurea Compounds / adverse effects*
  • Protein Kinase Inhibitors / administration & dosage
  • Recurrence
  • Sorafenib
  • Ventriculoperitoneal Shunt / adverse effects*

Substances

  • Phenylurea Compounds
  • Protein Kinase Inhibitors
  • Niacinamide
  • Sorafenib

Associated data

  • ClinicalTrials.gov/NCT01338857